Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

被引：10

作者：

Memoli, Mara ^{[1
,2
]}

Paviglianiti, Annalisa ^{[1
]}

Malard, Florent ^{[1
,3
,4
]}

Battipaglia, Giorgia ^{[1
,4
]}

Brissot, Eolia ^{[1
,3
,4
]}

Mediavilla, Clemence ^{[1
,4
]}

Bianchessi, Antonio ^{[1
,5
]}

Banet, Anne ^{[1
]}

Van de Wyngaert, Zoe ^{[1
]}

Ledraa, Tounes ^{[1
]}

Belhocine, Ramdane ^{[1
]}

Sestili, Simona ^{[1
]}

Lapusan, Simona ^{[1
]}

Hirsch, Pierre ^{[3
,4
,6
]}

Favale, Fabrizia ^{[3
,4
,6
]}

Boussaroque, Agathe ^{[3
,4
,6
]}

Bonnin, Agnes ^{[1
]}

Vekhoff, Anne ^{[1
]}

Legrand, Ollivier ^{[1
,3
,4
]}

Mohty, Mohamad ^{[1
,3
,4
]}

Dulery, Remy ^{[1
,3
,4
]}

机构：

[1] St Antoine Hosp, AP HP, Dept Hematol & Cellular Therapy, 184 Rue Faubourg St Antoine, F-75012 Paris, France

[2] Univ Naples Federico II, Hematol & Hematopoiet Stem Cell Transplant Ctr, Dept Med & Surg, Naples, Italy

[3] INSERM, UMRs 938, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP, Paris, France

[5] Univ Pavia, Dept Mol Med, Pavia, Italy

[6] Hop St Antoine, AP HP, Serv Hematol Biol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Thiotepa; busulfan; fludarabine; HSCT; TBF; myelofibrosis; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; LEUKEMIA WORKING PARTY; HAPLOIDENTICAL TRANSPLANTATION; EUROPEAN-SOCIETY; RISK-FACTORS; MARROW; SPLENECTOMY; RUXOLITINIB; MANAGEMENT;

D O I：

10.1080/10428194.2020.1827246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

引用

页码：419 / 427

页数：9

共 50 条

[1] Thiotepa-busulfan-fludarbine as Conditioning Regimen for Patients with Myelofibrosis undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience
Memoli, Mara
Paviglianiti, Annalisa
Malard, Florent
Battipaglia, Giorgia
Brissot, Eolia
Mediavilla, Clemence
Bianchessi, Antonio
Banet, Anne
Van de Wyngaert, Zoe
Ledraa, Tounes
Belhocine, Ramdane
Sestili, Simona
Lapusan, Simona
Bonnin, Agnes
Vekhoff, Anne
Legrand, Ollivier
Mohty, Mohamad
Dulery, Remy
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 307 - 308
[2] Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
Battipaglia, Giorgia
Mauff, Katya
Wendel, Lotus
Angelucci, Emanuele
Mohty, Mohamad
Arcese, William
Santarone, Stella
Rubio, Marie Therese
Kroger, Nicolaus
Fox, Maria Laura
Blaise, Didier
Iori, Anna Paola
Fanin, Renato
Chalandon, Yves
Pioltelli, Pietro
Marotta, Giuseppe
Chiusolo, Patrizia
Sever, Matjaz
Solano, Carlos
Contentin, Nathalie
de Wreede, Liesbeth C.
Czerw, Tomasz
Hernandez-Boluda, Juan Carlos
Hayden, Patrick
McLornan, Donal
Yakoub-Agha, Ibrahim
BONE MARROW TRANSPLANTATION, 2021, 56 (07) : 1593 - 1602
[3] Fludarabine, busulfan, and thiotepa may be a promising conditioning regimen for myelofibrosis patients undergoing allogeneic stem cell transplantation
Shouval, Roni
Vega, Yakov
Fein, Joshua A.
Danylesko, Ivetta
Tov, Noga Shem
Yerushalmi, Ronit
Nagler, Arnon
Shimoni, Avichai
BONE MARROW TRANSPLANTATION, 2019, 54 : 204 - 205
[4] Thiotepa-treosulfan-fludarabine (ttf) as conditioning regimen in patients undergoing allogeneic hematopoietic stem cell transplantation (allohsct) for myelofibrosis or myelodysplastic syndrome: A single center experience
Canale, F. A.
Porto, G.
Provenzano, P. F.
Naso, V.
Moscato, T.
Pugliese, M.
Loteta, B.
Irrera, G.
Console, G.
Ferreri, A.
Martino, M.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 236 - 236
[5] THIOTEPA-TREOSULFAN-FLUDARABINE (TTF) AS CONDITIONING REGIMEN IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) FOR MYELOFIBROSIS
Canale, Filippo Antonio
Porto, Gaetana
Verduci, Chiara
Celentano, Maria
Loteta, Barbara
Pugliese, Marta
Naso, Virginia
Moscato, Tiziana
Irrera, Giuseppe
Console, Giuseppe
Ferreri, Anna
Picardi, Alessandra
Martino, Massimo
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 496 - 497
[6] Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis
Shouval, Roni
Vega, Yakov
Fein, Joshua A.
Danylesko, Ivetta
Tov, Noga Shem
Yerushalmi, Ronit
Sobas, Marta
Czyz, Anna
Nagler, Arnon
Shimoni, Avichai
BONE MARROW TRANSPLANTATION, 2020, 55 (01) : 147 - 156
[7] Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis
Roni Shouval
Yakov Vega
Joshua A. Fein
Ivetta Danylesko
Noga Shem Tov
Ronit Yerushalmi
Marta Sobas
Anna Czyż
Arnon Nagler
Avichai Shimoni
Bone Marrow Transplantation, 2020, 55 : 147 - 156
[8] Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
Giorgia Battipaglia
Katya Mauff
Lotus Wendel
Emanuele Angelucci
Mohamad Mohty
William Arcese
Stella Santarone
Marie Therese Rubio
Nicolaus Kroger
Maria Laura Fox
Didier Blaise
Anna Paola Iori
Renato Fanin
Yves Chalandon
Pietro Pioltelli
Giuseppe Marotta
Patrizia Chiusolo
Matjaz Sever
Carlos Solano
Nathalie Contentin
Liesbeth C. de Wreede
Tomasz Czerw
Juan Carlos Hernandez-Boluda
Patrick Hayden
Donal McLornan
Ibrahim Yakoub-Agha
Bone Marrow Transplantation, 2021, 56 : 1593 - 1602
[9] ROLE OF THIOTEPA DOSE IN THE CONDITIONING REGIMEN THIOTEPA-BUSULFAN-FLUDARABINE (TBF) FOR HAPLOIDENTICAL TRANSPLANTS
Cigana, C.
Patriarca, F.
Lazzarotto, D.
Geromin, A.
Sperotto, A.
Battista, M. L.
Cerno, M.
Medeot, M.
Perali, G.
Ventura, G.
De Marchi, R.
Fanin, R.
HAEMATOLOGICA, 2016, 101 : S115 - S116
[10] Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvement: Insights from a single center
Huang, Xianbo
Wu, Xianhui
Wang, Shasha
Ren, Yanling
Xu, Yu
Mei, Chen
Jin, Jie
Tong, Hongyan
Qian, Jiejing
LEUKEMIA RESEARCH, 2024, 147

← 1 2 3 4 5 →